124 related articles for article (PubMed ID: 10396687)
1. [Susceptibilities of Enterococcus faecium, PRSP and MRSA to RP59500 and their correlations with those to other drugs].
Inoue M; Kubo S; Saito A; Ubukata K; Shimizu Y; Igari J; Watanabe A; Oguri T; Kawai T; Kobayashi Y; Hayashi M; Shiba K; Sakamoto M; Kanno H; Tokue Y; Yamaguchi K; Miyazaki S; Higashitsutsumi M; Sakamoto M; Inamatsu T; Kohno S; Tomono K; Shimada J; Kaku M; Ueda Y
Jpn J Antibiot; 1999 Apr; 52(4):302-12. PubMed ID: 10396687
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of vancomycin and other antimicrobial agents against methicillin-resistant staphylococcus aureus and enterococcus faecium in the Tohoku district of Japan.
Lutfor AB; Kikuchi T; Tokue Y; Takahashi H; Shoji S; Fujimura S; Nukiwa T; Watanabe A
Chemotherapy; 1998; 44(5):318-23. PubMed ID: 9732146
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Cockerill FR; Steckelberg JM
Diagn Microbiol Infect Dis; 1998 Feb; 30(2):89-92. PubMed ID: 9554174
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
5. Testing the efficacy of a molecular surveillance network: methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREF) genotypes in six hospitals in the metropolitan New York City area. The BARG Initiative Pilot Study Group. Bacterial Antibiotic Resistance Group.
de Lencastre H; Severina EP; Roberts RB; Kreiswirth BN; Tomasz A
Microb Drug Resist; 1996; 2(3):343-51. PubMed ID: 9158794
[TBL] [Abstract][Full Text] [Related]
6. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
Nakashio S; Iwasawa H; Iino S; Shimada J
Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
[TBL] [Abstract][Full Text] [Related]
7. [In vitro activities of quinupristin/dalfopristin in combination with vancomycin and gatifloxacin against Staphylococcus aureus and Enterococcus faecium clinical isolates].
Gülden E; Ermertcan S
Mikrobiyol Bul; 2009 Jan; 43(1):53-60. PubMed ID: 19334380
[TBL] [Abstract][Full Text] [Related]
8. [Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections].
Li JT; Li Y; Wang J;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):365-74. PubMed ID: 12820911
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Steckelberg JM
Diagn Microbiol Infect Dis; 2000 Nov; 38(3):177-9. PubMed ID: 11109018
[TBL] [Abstract][Full Text] [Related]
11. [An epidemiological investigation for MRSA and PRSP in Kinki area. Kinki Infection Working Group].
Mikasa K; Sawaki M; Konishi M; Maeda K; Tsujimoto M; Mori K; Narita N; Koizumi A; Sano R; Masutani T
Kansenshogaku Zasshi; 1998 Jul; 72(7):701-6. PubMed ID: 9745219
[TBL] [Abstract][Full Text] [Related]
12. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial therapy of multidrug-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus.
Cunha BA
Med Clin North Am; 2006 Nov; 90(6):1165-82. PubMed ID: 17116442
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens.
Severina E; Severin A; Tomasz A
J Antimicrob Chemother; 1998 Mar; 41(3):341-7. PubMed ID: 9578160
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.
Collins LA; Malanoski GJ; Eliopoulos GM; Wennersten CB; Ferraro MJ; Moellering RC
Antimicrob Agents Chemother; 1993 Mar; 37(3):598-601. PubMed ID: 8460927
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea.
Hwang SH; Kim MN; Pai CH; Huh DH; Shin WS
Yonsei Med J; 2000 Oct; 41(5):563-9. PubMed ID: 11079615
[TBL] [Abstract][Full Text] [Related]
17. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
Ikemoto H; Ito C; Yoshida T; Watanabe K; Mori T; Ohno I; Okada S; Igari J; Arakawa M; Igarashi K; Oguri T; Okada M; Ozaki K; Terai T; Aoki N; Inoue H; Nakadate T; Kitamura N; Sekine O; Suzuki Y; Ando M; Suga M; Sato K; Nakata K; Kusano N
Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
[TBL] [Abstract][Full Text] [Related]
18. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium.
Ristow TA; Noskin GA; Warren JR; Peterson LR
Microb Drug Resist; 1995; 1(4):335-9. PubMed ID: 9158806
[TBL] [Abstract][Full Text] [Related]
20. [Report of questionnaire survey for methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae in the Kinki District].
Morimoto K; Fujimoto M
Kansenshogaku Zasshi; 1999 Jun; 73(6):584-92. PubMed ID: 10423949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
